- An innovative add-on feature for the 3D-Bioplotter, the
PrintRoll platform was designed to enable 3D printing of
cylindrical medical solutions for adults and children and therefore
offers a range of standard and custom drum diameters
- The PrintRoll platform further solidifies the 3D-Bioplotter’s
premier position in the field of bioprinting. Widely recognized as
the world’s first commercial bioprinter1, the 3D-Bioplotter has
enjoyed continuous improvements for 20+ years that make it a proven
solution that scales from R&D to end-use part
manufacturing
- The U.S. Food and Drug Administration (FDA) recently granted
510(k) clearance to Chicago-based Dimension Inx for its CMFlex™, a
bone graft substitute regeneration product developed and
manufactured on the 3D-Bioplotter
- Available in two models, the Developer and Manufacturer,
3D-Bioplotter offers modular functionality, such as eight different
printheads, so users can enhance their printer for years after
purchase with new features like PrintRoll
- 3D-Bioplotter is also the world’s most cited and researched
bioprinter in peer-reviewed scientific and medical journals, with
more than 2,490 citations and 600 research papers directly produced
with the system
Desktop Health — the trusted production-grade medical 3D
printing brand of Desktop Metal, Inc. (NYSE: DM) — today announced
a breakthrough in bioprinting with the launch of PrintRoll™, an
innovative rotating build platform that can produce intelligent
tubular solutions for the body’s vascular, digestive, respiratory,
and reproductive channels on the 3D-Bioplotter premier bioprinting
system.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230724680554/en/
Nicole Black, Ph.D., VP of Biomaterials
and Innovation at Desktop Health, examines two tubular medical
devices printed on the new 3D-Bioplotter® PrintRoll™ rotating build
platform in medical-grade materials. PrintRoll is designed to
enable new medical solutions for the body’s thousands of miles of
internal channels, such as vascular, digestive, and other systems.
(Photo: Business Wire)
The 3D-Bioplotter is a highly sophisticated extrusion-based 3D
printer that processes liquids, melts, pastes, gels, or other
materials, including cells, through a needle tip on a Swiss-made,
3-axis gantry system with high accuracy and temperature, sterility,
and design controls. 3D-Bioplotter offers eight printheads with the
widest range of temperatures in bioprinting — from 2°C to 500°C
(35.6°F to 932°F) — enabling complex, multi-material medical
parts.
The PrintRoll add-on feature has been in development since 2019
as part of a collaboration with Johannes Gutenberg University
Mainz, a public research university in Mainz, Germany.
“We are proud to offer the first bioprinting tool specifically
designed to develop medical solutions for the thousands of miles of
channels found in the human body,” said Ric Fulop, Founder and CEO
of Desktop Metal. “Desktop Health exists to deliver 3D printing
solutions that improve patient lives, and we are confident that
PrintRoll, offered exclusively on the 3D-Bioplotter, will enable
all-new regenerative innovations. We look forward to seeing what
our customers will create next with this exciting new tool.”
Visit TeamDM.com/3DBioplotterBrochure to see a
video of the PrintRoll in action and download the latest
3D-Bioplotter brochure, which chronicles 20+ years of innovations
on the bioprinter by regenerative medicine experts.
How PrintRoll Works
The PrintRoll platform attaches to the modular build plate of
the 3D-Bioplotter and features a motor-driven rotating mandrel with
spring-loaded, easily exchangeable drums of different sizes.
Rotating speed is tightly controlled by the 3D-Bioplotter’s
easy-to-use software.
As the PrintRoll tool rotates, the printhead moves back and
forth depositing material on the surface in the desired design. For
example, polycaprolactone (PCL), a medical-grade, biodegradable
plastic used in many FDA-cleared implants and devices, hardens
quickly on the drum after the melted material is printed. In
bioprinting, users typically produce a structure or scaffold in a
stiff or flexible biocompatible material that is designed to repair
and integrate with cells of the body, sometimes degrading after a
certain period of time.
The PrintRoll comes with a 10 mm diameter drum – with 20 mm and
40 mm sizes available – designed to accommodate the development of
solutions for a variety of human channels, which vary based on age
and gender. Standard diameter sizes generally correspond to the
diameters of the femoral artery (~10 mm), trachea (~10-20 mm),
fallopian tube (~5-15 mm), aorta (~25 mm) esophagus (~30 mm), and a
range of intestine segments (~40-100 mm).
The PrintRoll system supports printing hollow cylindrical
structures up to 140 mm in length, depending on the printhead used.
Custom sizes may also be available.
“Up until now, the creation of thin-walled cylindrical devices
with complex structured walls has been challenging to accomplish
with regenerative materials, such as hydrogels,” said Nicole Black,
Ph.D., VP of Biomaterials and Innovation at Desktop Health. “With
the PrintRoll, materials are patterned directly on top of a
substrate that rolls as the printhead also moves, supporting the
deposited layers and therefore expanding the palette of materials
that can be 3D printed into these important structures. Following
printing, devices can be removed from the PrintRoll, leaving
high-resolution and reproducible parts that customers have come to
expect from the 3D-Bioplotter.”
The PrintRoll comes with a library of honeycomb designs and
standard printing parameters for common materials. The PrintRoll
platform, which is compatible with 4th Generation 3D-Bioplotter
models, is available for pre-order now, with shipping expected in
the fourth quarter. Contact Desktop Health to learn more at
TeamDM.com/3DBioplotterMoreInfo.
3D-Bioplotter® Continues Pioneering Bioprinting
PrintRoll continues the long history of bioprinting innovations
on the world’s most researched bioprinting system, as detailed in
the last 3D-Bioplotter brochure.
This tradition is also continued with CMFlex™ — the first 3D
printed regenerative bone graft substitute product cleared by the
FDA and the first such clearance based on manufacturing on the
3D-Bioplotter. Developed by Dimension Inx, CMFlex is an easy-to-use
flexible bone graft product that is 3D printed on a standard
3D-Bioplotter Manufacturer model. This new product is an
alternative to an autograft, in which a physician intrusively
harvests bone from one area of a patient’s body to repair damaged
or diseased bone elsewhere in the body.
“The recent FDA clearance of CMFlex by Dimension Inx is a
breakthrough for the field of additive, regenerative medicine – one
that clearly showcases the robustness of the 3D-Bioplotter,” said
Lou Azzarra, President of Desktop Health. “Commercial milestones
like this often take many years, and we congratulate the entire
team at Dimension Inx on this achievement.”
Visit TeamDM.com/3DBioplotterBrochure to download
our latest brochure, which details how Dimension Inx developed
CMFlex for commercialization.
About Desktop Metal
Desktop Metal (NYSE:DM) is driving Additive Manufacturing
2.0, a new era of on-demand, digital mass production of industrial,
medical, and consumer products. Our innovative 3D printers,
materials, and software deliver the speed, cost, and part quality
required for this transformation. We’re the original inventors and
world leaders of the 3D printing methods we believe will empower
this shift, binder jetting and digital light processing. Today, our
systems print metal, polymer, sand and other ceramics, as well as
foam and recycled wood. Manufacturers use our technology worldwide
to save time and money, reduce waste, increase flexibility, and
produce designs that solve the world’s toughest problems and enable
once-impossible innovations. Learn more about Desktop Metal and our
#TeamDM brands at www.desktopmetal.com.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws. Forward-looking
statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this document, including but not
limited to the risks and uncertainties set forth in Desktop Metal,
Inc.'s filings with the U.S. Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Desktop Metal, Inc. assumes no obligation and does
not intend to update or revise these forward-looking statements,
whether as a result of new information, future events, or
otherwise.
_______________________ 1“Hence, 3D Bioplotter® which was
capable of cell-laden bioprinting, could be defined as the first
commercial 3D bioprinter in the world.” Gu Z, Fu J, Lin H, He Y.
Development of 3D bioprinting: From printing methods to biomedical
applications. Asian J Pharm Sci. 2020 Sep;15(5):529-557. doi:
10.1016/j.ajps.2019.11.003. Epub 2019 Dec 17. PMID: 33193859;
PMCID: PMC7610207.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610207/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230724680554/en/
Media Relations: Sarah Webster
sarahwebster@desktopmetal.com (313) 715-6988
Investor Relations: Jay Gentzkow
jaygentzkow@desktopmetal.com (781) 730-2110
Desktop Metal (NYSE:DM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Desktop Metal (NYSE:DM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024